Healthcare: Were These The 3 Most Promising Biotech Stocks To Buy After ASCO?

<p>Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week.<br /> <br /> Sponsored link: <strong><a href= "http://www.casper.com/fool">http://www.casper.com/fool</a></strong> code fool.</p>